T-Cell Project: Prospective Collection of Data in Patients With Peripheral ... | Recruiting
T-Cell Project: Prospective Collect... | Recruiting
T-Cell Project: Prospective Collection of Data in Patients With Peripheral T-Cell Lymphoma

Location not identified by Google services

Location data is sourced from multiple external providers and UKCTG is not responsible for and cannot guarantee the accuracy of data.

Medical Conditions
  • Lymphoma, T-Cell, Peripheral
Primary Contact Details
Monica Bellei, MSc, PhD
+39 059 422 4020
See all trial contact details
Recruitment Status
Recruiting
Trial source and source ID number
NCT01142674

We need your help to advance medical research

You can help accelerate the discovery of cures of medical conditions by signing up and creating a profile. By doing so you can register your interest in clinical trials and researchers will be able to get in touch about trials that are suitable for you.

This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Summary
The designed study follows up the retrospective previous one by the International T-cell Non-Hodgkin's Lymphoma Study Group (International Peripheral T-Cell Lymphoma Project).

It is designed as a prospective collection of information potentially useful to predict the prognosis of newly diagnosed patients with the more frequent subtypes of Peripheral T-cell lymphoma (Peripheral T-cell lymphoma unspecified and Angioimmunoblastic T-cell lymphoma) and to better define clinical characteristics and outcome of the more uncommon subtypes
Research Details
  • Peripheral T-cell lymphomas (PTCLs) comprise a heterogeneous group of neoplasms that are derived from post-thymic lymphoid cells at different stages of differentiation with different morphological patterns, phenotypes, and clinical presentations. PTCLs are highly diverse, reflecting the diverse cells from which they can originate. Peripheral T-Cell Lymphomas account for 5-10% of all lymphoproliferative disorders in the Western hemisphere, with an overall incidence of 0.5-2 per 100,000 per year, and have a striking epidemiological distribution, with higher incidence in Asia.

    The clinical features of PTCLs are extremely heterogeneous. PTCLs express even more clinical diversity than B-cell NHLs, and there is a close, though not absolute, relationship between some unusual clinical features and certain histological subtypes. Despite efforts to transferring to patients with T-cell lymphomas the most recent advances in the treatment of other subtypes of B-cell lymphomas, the prognosis of patients with PTCL is still poor an, unfortunately, the optimal therapy for PTCL is still unknown. The complete response rate is rather low, ranging from 40% to 50% with a median Relapse Free Survival (RFS) of 2-3 years. As a consequence of the aggressiveness of the disease and of the low efficacy of available salvage treatments, Overall Survival (OS) is also short and the long-term survival rate is lower than 10% in many series.

    To better define the clinical outcome of PTCL-NOS, the Intergruppo Italiano Linfomi (IIL, now Fondazione Italiana Linfomi, FIL) performed a large study on 385 patients diagnosed and treated in the 1990s and defined a prognostic model specifically devised for patients with this uncommon disease (Gallamini, A. et al Blood, 2004. 103(7): p. 2474-9). In addition to defining a prognostic model specifically devised for PTCL-NOS, the FIL study confirms the relevance of research on series of clearly defined cases in order to the development of rationally designed and potentially more-efficacious treatment modalities. More recently, the role of biological features of the disease is emerging as an important issue not only for understanding its pathogenesis but also for prognosis and for addressing specific biologic targets altered in the neoplasia. Significant progress in the prognosis of PTCL can be expected from the novel, sophisticated, and powerful technologies of genomics and proteomics, which will allow more reliable subtyping of PTCL into distinct clinical groups characterized by different patterns of survival, as already demonstrated for some B-NHLs.

    One common limitation of existing studies on prognosis of PTCL is their retrospective nature. Currently available data are based on analysis performed on series collected over a long period of time. This aspect is very important as it may introduce relevant biases in the collected series. First classification systems have changed dramatically over time and cases may have been defined in differently based on diagnosis year. Second some clinical or laboratory data which now are considered as prognostic relevant may have not been determined in older series of patients. Third in a retrospective analysis there is no guarantee that collected series are based on real consecutive cases. These are the reasons why we thought it would be useful to start a new study based on the prospective registration in a short period of time of patients with diagnosis of Peripheral T-cell lymphoma for whom it would be possible collect an exhaustive set of clinical data and biological information.
Phase
N/A
Study Design
Observational Model: Cohort, Time Perspective: Prospective
Study Type
Observational
Intervention
Sorry, this information is not available
Intervention Type
See Interventions above
Primary Outcome Measures
    Overall Survival (OS); 5 years
Secondary Outcome Measures
    Event Free Survival (EFS); 5 years; Remission rate with initial therapy; End of front-line therapy; Progression Free Survival (PFS); 5-years
Publication(s)
Federico M, Bellei M, Pesce, E, Zucca E, Pileri S, Montoto S, Weisenburger DD, Ruediger T, KO YH, Liang R, Zinzani PL, Connors JM, Foss FM, Horwitz SM, Polliack A, Vose JM. T-Cell Project: an international, longitudinal, observational study of patients with aggressive peripheral T-cell lymphoma. Revista Brasileira de Hematologia e Hemoterapia 31(suppl 2):21-25,2009.; null; Federico M, Bellei M, Pesce EA, Zucca E, Pielri S, Montoto S, Weisenburger D, Rugiger T, Ko Y, Liang R, Zinzani PL, Connors J, Foss F, Horwitz S, Polliack A, Vose J. T-Cell Project: an international, prospective, observational study of patients with aggressive Peripheral T-cell Lymphoma. Analysis of the first 524 patients. 11 ICML, Lugano (Switzerland), 15-18 June 2011. Abs 241. Ann Oncol 22 (suppl 4), 2011; null; Bellei M, Chiattone CS, Luminari S, Pesce EA, Cabrera ME, de Souza CA, Gabús R, Zoppegno L, Zoppegno L, Milone J, Pavlovsky A, Connors JM, Foss FM, Horwitz SM, Liang R, Montoto S, Pileri SA, Polliack A, Vose JM, Zinzani PL, Zucca E, Federico M. T-cell lymphomas in South america and europe. Rev Bras Hematol Hemoter. 2012;34(1):42-7. doi: 10.5581/1516-8484.20120013.; 23049383; Federico M, Bellei M, Luminari S, Horwitz SM, Montoto S, Zucca E, Pileri SA, Ko YH, Zinzani PL, Connors JM, Foss FM, Polliack A, Cabrera ME, Kim WS, Spina M, De Souza CA, Bobillo Varela S, Dlouhy I, Advani RH, Vose J and T-Cell Project. CD30+ expression in Peripheral T-cell lymphomas (PTCLs): A subset analysis from the international, prospective T-Cell Project. Journal of Clinical Oncology, 2015 ASCO Annual Meeting (May 29 - June 2, 2015).Vol 33, No 15_suppl (May 20 Supplement), 2015: 8552; null; Federico M, Bellei M, Pesce EA, et al. T-Cell Project: an international, prospective, observational study of patients with aggressive Peripheral NK/T-Cell Lymphoma: Lesson from the first 1308 patients. 13 ICML, Lugano (Switzerland) 17-20 June, 2015. Abstract 070. Hematol Oncol 2015; 33(Suppl1):100-180; null; Bellei M, Marcheselli L, Pesce EA, et al. Clinical Characteristics and Patterns of Care of Patients (pts) with Peripheral T-cell Lymphoma (PTCLs) according to age at time of diagnosis: A T-Cell Project snapshot. 13 ICML, Lugano (Switzerland) 17-20 June, 2015. Abstract 231. Hematol Oncol 2015; 33(Suppl1):181-243; null; Horwitz SM, Bellei M, Marcheselli L, et al. The role of transplant in the treatment of Peripheral T-cell Lymphomas (PTCLs): an analysis from the T-cell Project database. 13 ICML, Lugano (Switzerland) 17-20 June, 2015. Abstract 247. Hematol Oncol 2015; 33(Suppl1):181-243; null; Bellei M, Sabattini E, Pesce EA, Ko YH, Kim WS, Cabrera ME, Martinez V, Dlouhy I, Paes RP, Barrese T, Vassallo J, Tarantino V, Vose J, Weisenburger D, Rüdiger T, Federico M, Pileri S. Pitfalls and major issues in the histologic diagnosis of peripheral T-cell lymphomas: results of the central review of 573 cases from the T-Cell Project, an international, cooperative study. Hematol Oncol. 2016 Jun 3. doi: 10.1002/hon.2316. [Epub ahead of print]; 27255982
Result Reports
Check availability of results on the Clinicaltrials.gov website
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Gender
Both
Age Range
18 Years - N/A
Who Can Participate
Patients
Number of Participants
2000
Participant Inclusion Criteria
    Inclusion Criteria:

    1. Previously-untreated patients with de novo diagnosis of peripheral T-cell or NK/T-cell lymphoma:

    - Peripheral T-cell lymphoma unspecified;

    - Peripheral T-cell lymphoma, lymphoepithelioid variant;

    - Peripheral T-cell lymphoma, T-zone variant ;

    - Peripheral T-cell lymphoma, parafollicular variant ;

    - Angioimmunoblastic T-cell lymphoma;

    - Nasal NK/T-cell lymphoma;

    - NK/T-cell lymphoma, nasal time;

    - Anaplastic large-cell lymphoma, T/null cell, ALK+, primary systemic type

    - Anaplastic large-cell lymphoma, T/null cell, ALK-, primary systemic type

    - Anaplastic large cell lymphoma, small cell variant, ALK+

    - Anaplastic large cell lymphoma, lymphohistiocytic variant, ALK+

    - Enteropathy- type T-cell lymphoma;

    - Hepatosplenic T-cell lymphoma;

    - Peripheral gamma-delta T-cell lymphoma;

    - Subcutaneous panniculitis-like T-cell lymphoma;

    - Unclassifiable peripheral T-cell Lymphoma

    - Unclassifiable NK-cell lymphoma

    2. Age over 18

    3. Tissue biopsies adequate for diagnosis and classification and available for centralized review

    4. Clinical data including baseline information on disease localization and laboratory parameters at staging, features of treatment adopted and assurance of follow-up updating for at least 5 years are requested

    5. Written informed consent

    Exclusion Criteria:

    1. Age < 18

    2. Diagnosis of T-cell or NK-cell leukemia or proliferation and other than mature types including:

    - Adult T-cell leukemia/lymphoma;

    - Blastic NK-cell leukemia/lymphoma;

    - Aggressive NK-cell leukemia

    - T-cell large granular lymphocytic leukemia

    - T-cell large granular lymphocytic proliferation

    - NK-cell large granular lymphocytic proliferation

    - T-cell prolymphocytic leukemia

    - Precursor T-cell lymphoblastic leukemia/lymphoma

    - Mycosis fungoides;

    - Sézary syndrome;

    - Primary cutaneous ALCL
Participant Exclusion Criteria
This is in the inclusion criteria above
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Trial Location(s)
Manchester
M20 4BX
Southampton General Hospital
Southampton
England
SO16 6YD
London
EC1A 7BE
Pfizer Investigational Site
Birmingham
B15 2TT
Royal Wolverhampton Hospitals Trust - Research and Development
Wolverhampton
WV10 OQP
Site GB44005
London
SE19RT
Newcastle University
Newcastle upon Tyne
NE17RU
Trial Contact(s)
Primary Trial Contact
Monica Bellei, MSc, PhD
+39 059 422 4020
Other Trial Contacts
Emanuela A. Pesce, MSc,PhD
+39 059 422 2577
Countries Recruiting
Argentina, Brazil, Chile, China, France, Israel, Italy, Korea, Republic of, Slovakia, Spain, Switzerland, United Kingdom, United States, Uruguay
This information is designed to help you decide whether this trial is of interest. In some cases it is provided as a link to more detailed patient information or it may still be awaited from the organisation running the trial. Please look again shortly if the information you need is not here or, if named, contact the researcher named above.
Scientific Title
Prospective Collection of Data in Pts With Peripheral T-Cell Lymphoma: PTCL,NOS;AITL; Extranodal NK/T-cell;Enteropathy-type; Hepatosplenic γ-δ; Subcutaneous Panniculitis-like; ALCL,Primary Systemic Type. By the Intl. T-Cell Lymphoma Project
EudraCT Number
Not available for this trial
Funder(s)
  • Fondazione Italiana Linfomi ONLUS
  • International Peripheral T-Cell Lymphoma Project (Study group)
Other Study ID Numbers
T-Cell Project
Sponsor(s)
Associazione Angela Serra per la ricerca sul cancro
Key Dates

Recruitment Start Date

Sep 2006

Recruitment End Date

Dec 2017

Trial Start Date
Date Not Available
Trial End Date
Date Not Available
Date added to source

10 Jun 2010

Date updated in source

08 Aug 2016